← FDA DRUG APPROVALS

FDA ANDA · ANDA075944

LISINOPRIL

Sponsor: SUN PHARM INDS LTD

APPLICATION
ANDA075944
TYPE
ANDA
ORIGINAL APPROVAL
2002-07-01
LATEST ACTION
2020-04-27
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LISINOPRILPrescription
LISINOPRIL 40MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 20MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 5MG · TABLET · ORAL

Approval history

2020-04-27Labeling · Supplement 29 · standardAP
2016-09-16Labeling · Supplement 28 · standardAP
2015-11-25Labeling · Supplement 27 · standardAP
2015-08-25Labeling · Supplement 26 · standardAP
2015-08-25Labeling · Supplement 24 · standardAP
2015-08-25Labeling · Supplement 25 · standardAP
2013-08-05Labeling · Supplement 22 · standardAP
2013-08-05Labeling · Supplement 20 · standardAP
2013-08-05Labeling · Supplement 23 · standardAP
2013-08-05Labeling · Supplement 21 · standardAP
2010-03-12Labeling · Supplement 19AP
2010-03-08Labeling · Supplement 18AP
2010-02-22Labeling · Supplement 17AP
2007-09-24Labeling · Supplement 12AP
2003-02-11Manufacturing (CMC) · Supplement 1AP
2003-02-11Labeling · Supplement 2AP
2002-07-01OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →